The medical intervention of primary hypertension

Antihypertensive intervention in primary hypertension

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048184

Enrollment

Unknown

Registered

2021-07-04

Start date

2021-07-10

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Experimental group1:Oral calcium channel blockers

Experimental group2:Oral angiotensin type II receptor blockers

Experimental group3:Oral calcium channel blocker + angiotensin type II receptor blocker

Control group:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Local residents of Jiangsu (Suzhou and Nanjing); 2. Primary hypertension (SBP>=140mmHg and/or DBP>=90mmHg, based on 3 times independent measurements in the morning before taking breakfast).

Exclusion criteria

Exclusion criteria: 1. Diabetes or take anti-diabetic medications, liver and kidney disfunction, have other cardiovascular events(e.g., Myocardial infarction, unstable angina pectoris, cerebrovascular disease)in the past 6 months; 2. Abnormal thyroid function, abnormal blood coagulation, tumor patients, pregnant women, breastfeeding or preparing to conceive.

Design outcomes

Primary

Measure	Time frame
blood pressure;	—

Secondary

Measure	Time frame
Vascular function;gut microbiome;plasma metabolome;urine metabolome;	—

Countries

China

Contacts

Public ContactKong Xiangqing

Nanjing Medical University

kongxq@njmu.edu.cn+86 13951610265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026